These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
480 related articles for article (PubMed ID: 18794552)
1. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. Vanden Bempt I; Van Loo P; Drijkoningen M; Neven P; Smeets A; Christiaens MR; Paridaens R; De Wolf-Peeters C J Clin Oncol; 2008 Oct; 26(30):4869-74. PubMed ID: 18794552 [TBL] [Abstract][Full Text] [Related]
2. [Analysis of HER2 gene status in breast cancer with HER2 protein overexpression]. Zeng X; Liang ZY; Wu SF; Zhou WX; Gao J; Liu TH Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):584-8. PubMed ID: 17134563 [TBL] [Abstract][Full Text] [Related]
3. Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy. Tse CH; Hwang HC; Goldstein LC; Kandalaft PL; Wiley JC; Kussick SJ; Gown AM J Clin Oncol; 2011 Nov; 29(31):4168-74. PubMed ID: 21947821 [TBL] [Abstract][Full Text] [Related]
4. Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer. Zhu X; Lu Y; Lu H; Yang W; Tu X; Cai X; Zhou X Hum Pathol; 2011 Oct; 42(10):1499-504. PubMed ID: 21676436 [TBL] [Abstract][Full Text] [Related]
5. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Wang S; Hossein Saboorian M; Frenkel EP; Haley BB; Siddiqui MT; Gokaslan S; Hynan L; Ashfaq R Mod Pathol; 2002 Feb; 15(2):137-45. PubMed ID: 11850542 [TBL] [Abstract][Full Text] [Related]
7. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17. Simonetti S; Russo R; Ciancia G; Altieri V; De Rosa G; Insabato L Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884 [TBL] [Abstract][Full Text] [Related]
8. Chromosome 17 polysomy: correlation with histological parameters and HER2NEU gene amplification. Orsaria M; Khelifa S; Buza N; Kamath A; Hui P J Clin Pathol; 2013 Dec; 66(12):1070-5. PubMed ID: 23908451 [TBL] [Abstract][Full Text] [Related]
9. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. Hofmann M; Stoss O; Gaiser T; Kneitz H; Heinmöller P; Gutjahr T; Kaufmann M; Henkel T; Rüschoff J J Clin Pathol; 2008 Jan; 61(1):89-94. PubMed ID: 17412870 [TBL] [Abstract][Full Text] [Related]
10. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. McCormick SR; Lillemoe TJ; Beneke J; Schrauth J; Reinartz J Am J Clin Pathol; 2002 Jun; 117(6):935-43. PubMed ID: 12047146 [TBL] [Abstract][Full Text] [Related]
11. Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17. Vranic S; Teruya B; Repertinger S; Ulmer P; Hagenkord J; Gatalica Z Cancer; 2011 Jan; 117(1):48-53. PubMed ID: 20803611 [TBL] [Abstract][Full Text] [Related]
12. [Effects of polysomy 17 on HER-2 gene and protein expression and its clinicopathologic significance in breast cancer]. Li J; Xu BH; Wang JY; Li Q; Zhang P; Yuan P; Ma F; Fan Y; Cai RG; Li Q Zhonghua Yi Xue Za Zhi; 2013 Jan; 93(2):84-8. PubMed ID: 23648340 [TBL] [Abstract][Full Text] [Related]
13. [Clinicopathologic significance of chromosome 17 polysomy in breast cancer]. Lü YL; Zhong M; Liu L; Wei LX; Zhao P Zhonghua Bing Li Xue Za Zhi; 2008 Feb; 37(2):88-91. PubMed ID: 18681318 [TBL] [Abstract][Full Text] [Related]
14. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer. Hyun CL; Lee HE; Kim KS; Kim SW; Kim JH; Choe G; Park SY J Clin Pathol; 2008 Mar; 61(3):317-21. PubMed ID: 17761736 [TBL] [Abstract][Full Text] [Related]
15. Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification. Moelans CB; de Weger RA; van Diest PJ Breast Cancer Res Treat; 2010 Feb; 120(1):1-7. PubMed ID: 19760503 [TBL] [Abstract][Full Text] [Related]
16. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer. Lottner C; Schwarz S; Diermeier S; Hartmann A; Knuechel R; Hofstaedter F; Brockhoff G J Pathol; 2005 Apr; 205(5):577-84. PubMed ID: 15732132 [TBL] [Abstract][Full Text] [Related]
17. Assessing the impact of polysomy-17 on HER2 status and the correlations of HER2 status with prognostic variables (ER, PR, p53, Ki-67) in epithelial ovarian cancer: a tissue microarray study using immunohistochemistry and fluorescent in situ hybridization. Lin CK; Lin WL; Chen FL; Lee MY; Kuo JF; Ruan A; Tyan YS; Chiang H; Chou MC; Han CP Int J Gynecol Pathol; 2011 Jul; 30(4):372-9. PubMed ID: 21623202 [TBL] [Abstract][Full Text] [Related]
18. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Jimenez RE; Wallis T; Tabasczka P; Visscher DW Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908 [TBL] [Abstract][Full Text] [Related]
19. Genetic heterogeneity of HER2 in breast cancer: impact on HER2 testing and its clinicopathologic significance. Yang YL; Fan Y; Lang RG; Gu F; Ren MJ; Zhang XM; Yin D; Fu L Breast Cancer Res Treat; 2012 Aug; 134(3):1095-102. PubMed ID: 22476857 [TBL] [Abstract][Full Text] [Related]
20. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]